Nailyn Rasool1, Katherine Boudreault, Simmons Lessell, Sashank Prasad, Dean M Cestari. 1. Department of Ophthalmology (NR), Harkness Eye Institute, Columbia University, New York, New York; Deartment of Ophthalmology (KB), University of Montreal, Montreal, Quebec, Canada; Department of Ophthalmology (SL, DMC), Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; and Department of Ophthalmology (SP), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Tacrolimus (FK506, Prograf) is a potent immunosuppressant, which inhibits cytokine synthesis and blocks T-cell development. Optic neuropathy from tacrolimus toxicity is very uncommon but, when present, can result in severe vision loss. METHODS: Case series and review of the literature. RESULTS: We present 3 patients with tacrolimus optic neuropathy after bone marrow transplantation complicated by graft-vs-host disease and demonstrate the differing clinical and radiologic presentation of this presumed toxic optic neuropathy. CONCLUSIONS: Tacrolimus optic neuropathy can manifest in a multitude of clinical presentations and can have devastating visual consequences.
BACKGROUND:Tacrolimus (FK506, Prograf) is a potent immunosuppressant, which inhibits cytokine synthesis and blocks T-cell development. Optic neuropathy from tacrolimustoxicity is very uncommon but, when present, can result in severe vision loss. METHODS: Case series and review of the literature. RESULTS: We present 3 patients with tacrolimus optic neuropathy after bone marrow transplantation complicated by graft-vs-host disease and demonstrate the differing clinical and radiologic presentation of this presumed toxic optic neuropathy. CONCLUSIONS:Tacrolimus optic neuropathy can manifest in a multitude of clinical presentations and can have devastating visual consequences.